• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 7, 2019

View Archived Issues

AMDAC gives cautionary thumbs up to three-drug tuberculosis regimen

The FDA's Antimicrobial Drugs Advisory Committee (AMDAC) voted 14-4 Thursday in support of the use of TB Alliance's pretomanid as part of a combination regimen to treat the most resistant cases of tuberculosis (TB). Regimen was the key word. "I'm voting for a regimen, not a single drug," said Matthew Goetz, a professor at the David Geffen School of Medicine at the University of California-Los Angeles and chief of the infectious diseases division at the Veterans Affairs Greater Los Angeles Healthcare System. Read More

Ebola cases exceed 2,000 in DRC as stockpile dwindles

LONDON – The number of confirmed cases in the Ebola epidemic in the Democratic Republic of Congo (DRC) has reached 2,025, amid signs that control measures that have been effective in outbreaks elsewhere are unequal to the complex circumstances in the war-torn country. Read More

We're breaking up: Axovant calls off Benitec deal for gene therapy

Axovant Sciences Ltd. has terminated its $187.5 million license and collaboration agreement with Benitec Biopharma Ltd., a Sydney-based gene therapy company, regarding AXO-AAV-OPMD (formerly BB-301) for treating oculopharyngeal muscular dystrophy (OPMD). Read More

Nearing commercial stage, Cstone files first NDA, seeking nod for Tibsovo in Taiwan

HONG KONG – Aiming to expand its market in greater China, Cstone Pharmaceuticals Co. Ltd. submitted a new drug application (NDA) for Tibsovo (ivosidenib) to the Taiwan Food and Drug Administration (TFDA), seeking approval of the first drug to treat adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Read More

Family funds, accelerators bridge the gap for science too early for traditional VC rounds

PHILADELPHIA - While amounts raised through seed and series A venture capital rounds in 2018 have towered above previous years, indicating a growing interest in investing early, the money does not address a researcher's need to fund science at an even earlier stage, sometimes at the very beginnings of an idea. Read More

FDA issues draft guidance on enhancing diversity of trial participants

PHILADELPHIA – With a major gap remaining between the demographics of people enrolled in clinical trials and those most likely to use the drugs the FDA approves, the agency is pushing forward with new steps to tackle the complex problem, issuing a draft guidance on enhancing trial population diversity on Thursday. If successful, the move could complement the efforts of industry and its partners as they pursue everything from community outreach to simple logistical supports. Read More

Australia takes BIO 'by storm' with largest ever delegation

PHILADELPHIA – This year's Australian delegation saw the most impressive participation to date at the Biotechnology Innovation Organization's (BIO) 2019 conference, with more than 150 Australian companies participating as well as numerous government representatives. Read More

As investors favor oncology and rare disease, work in prevalent chronic disease takes backseat

PHILADELPHIA – Compared to oncology, chronic diseases such as cardiovascular disease, diabetes and dementia represent much more substantial costs to the overall U.S. health care system, yet investment and R&D innovation in those areas has been on a steady decline over the past decade or so, according to research compiled by the Biotechnology Innovation Organization (BIO). Read More

Regulatory front

Insys Therapeutics Inc., of Phoenix, entered a $225 million settlement to resolve separate criminal and civil investigations into its marketing of Subsys, a sublingual fentanyl spray approved by the FDA in 2012 for the treatment of breakthrough pain in cancer patients.  Read More

Other news to note

Bioventus LLC, of Durham, N.C., entered a collaboration agreement with tissue bank MTF biologics to co-develop a next-generation placental tissue product for treating musculoskeletal conditions, with an initial focus on knee osteoarthritis. Terms of the deal were not disclosed. Read More

Financings

Third Rock Ventures LLC, of Boston, said it closed an oversubscribed Third Rock Ventures V LP fund, raising $770 million. This new fund will support its ongoing strategy of discovering, launching and building innovative life sciences companies.  Read More

Clinical data for June 6, 2019

Read More

Regulatory actions for June 6, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe